Navigation Links
Treatment for extreme nausea, vomiting during pregnancy
Date:5/6/2009

rate compared to women who received no medication. As expected, metoclopramide was not associated with other serious side effects.

"This study validates our protocol," says Dr. Brard. "Clinical trials are not conducted on pregnant women, so we had to rely on data from prospective and retrospective studies in this case. We anticipate that other institutions will now be comfortable adopting this new treatment regime.

About hyperemis gravidarum

Hyperemis gravidarum, or severe nausea and vomiting of pregnancy, affects about one percent of pregnant women. If left untreated, it can result in severe weight loss, dehydration, or death. Symptoms to look out for include severe vomiting and nausea; incapacity to keep food down for two to three days; lack of energy.

According to Dr. Brard, women should not wait too long before seeking medical help. "The longer the symptoms continue, the longer the hospital stay," she says, adding most women with HG leave the hospital within three days and many are required to take medication throughout their pregnancy.

About the study:

"Metoclopramide and diphenhydramine in the treatment of hyperemisis gravidarum: Effectiveness and predictors of rehospitalization," published in European Journal of Obstetrics and Gynecology and Reproductive Biology, was authored by Anais Lacasse, Ema Ferreira and Anick Brard of the Universit de Montral and the Sainte-Justine University Hospital Centre and Amandine Lagoutte of the Universit de Bourgogne.


'/>"/>

Contact: Sylvain-Jacques Desjardins
sylvain-jacques.desjardins@umontreal.ca
514-343-7593
University of Montreal
Source:Eurekalert

Page: 1 2

Related biology news :

1. Nicotinic receptors may be important targets for treatment of multiple addictions
2. A new radiation therapy treatment developed for head and neck cancer patients
3. Restoring sight, advances in fertility treatments and better visibility for pilots at FIO
4. Presence of gene mutation helps guide thyroid cancer treatment
5. U of M begins nations first clinical trial using T-reg cells from cord blood in leukemia treatment
6. New genetic research into nicotine addiction shows promise for personalized treatment
7. Interleukin-8, key marker for colorectal cancer treatment
8. New class of drug offers hope to treatment-resistant AIDS patients
9. Paradigm shift in Alzheimerss research: new treatments
10. New research on structure of bones raises questions for treatment of osteoporosis
11. Major genetic breakthrough for ankylosing spondylitis brings treatment hope
Post Your Comments:
*Name:
*Comment:
*Email:
Other Biology Technology:Verifying Multichannel Pipettor Performance with Standard Dispense Solutions in the SpectraMax Plus (MaxLine Application Note #28) 2Verifying Multichannel Pipettor Performance with Standard Dispense Solutions in the SpectraMax Plus (MaxLine Application Note #28) 3Verifying Multichannel Pipettor Performance with Standard Dispense Solutions in the SpectraMax Plus (MaxLine Application Note #28) 4Verifying Multichannel Pipettor Performance with Standard Dispense Solutions in the SpectraMax Plus (MaxLine Application Note #28) 5Verifying Multichannel Pipettor Performance with Standard Dispense Solutions in the SpectraMax Plus (MaxLine Application Note #28) 6Verifying Multichannel Pipettor Performance with Standard Dispense Solutions in the SpectraMax Plus (MaxLine Application Note #28) 7Verifying Multichannel Pipettor Performance with Standard Dispense Solutions in the SpectraMax Plus (MaxLine Application Note #28) 8Verifying Multichannel Pipettor Performance with Standard Dispense Solutions in the SpectraMax Plus (MaxLine Application Note #28) 9Verifying Multichannel Pipettor Performance with Standard Dispense Solutions in the SpectraMax Plus (MaxLine Application Note #28) 10Verifying Multichannel Pipettor Performance with Standard Dispense Solutions in the SpectraMax Plus (MaxLine Application Note #28) 11Verifying Multichannel Pipettor Performance with Standard Dispense Solutions in the SpectraMax Plus (MaxLine Application Note #28) 12Verifying Multichannel Pipettor Performance with Standard Dispense Solutions in the SpectraMax Plus (MaxLine Application Note #28) 13Verifying Multichannel Pipettor Performance with Standard Dispense Solutions in the SpectraMax Plus (MaxLine Application Note #28) 14Verifying Multichannel Pipettor Performance with Standard Dispense Solutions in the SpectraMax Plus (MaxLine Application Note #28) 15UV Absorbance Measurements in SpectraMax Microplate Spectrophotometers MaxLine Application Note #32) 2UV Absorbance Measurements in SpectraMax Microplate Spectrophotometers MaxLine Application Note #32) 3UV Absorbance Measurements in SpectraMax Microplate Spectrophotometers MaxLine Application Note #32) 4UV Absorbance Measurements in SpectraMax Microplate Spectrophotometers MaxLine Application Note #32) 5UV Absorbance Measurements in SpectraMax Microplate Spectrophotometers MaxLine Application Note #32) 6Using the OligoGreen Oligonucleotide Quantitation Reagent in the Gemini XS, Gemini EM and SpectraMax M2 Microplate Readers (MaxLine Application Note #21) 2Using the OligoGreen Oligonucleotide Quantitation Reagent in the Gemini XS, Gemini EM and SpectraMax M2 Microplate Readers (MaxLine Application Note #21) 3Using the OligoGreen Oligonucleotide Quantitation Reagent in the Gemini XS, Gemini EM and SpectraMax M2 Microplate Readers (MaxLine Application Note #21) 4